Congenital Myasthenic Syndromes

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Congenital myasthenic syndromes (CMSs) stem from defects in endplate-associated proteins that compromise the safety margin of neuromuscular transmission by one or more distinct mechanisms. The identified syndromes stem from defects of choline acetyltransferase, acetylcholinesterase, β2-laminin, acetylcholine receptor subunits, rapsyn, MuSK, agrin, Dok-7, Nav1.4, and plectin. Distinct clinical clues can point to the disease protein but sometimes electrophysiological, structural, and genetic studies are required for diagnosis. Different types of CMSs mandate different types of therapy.

Original languageEnglish (US)
Title of host publicationNeuromuscular Disorders
PublisherWiley-Blackwell
Pages142-149
Number of pages8
ISBN (Print)0470654562, 9780470654569
DOIs
StatePublished - Sep 6 2011

Fingerprint

Congenital Myasthenic Syndromes
Plectin
Agrin
Laminin Receptors
Choline O-Acetyltransferase
Cholinergic Receptors
Acetylcholinesterase
Proteins
Safety
Therapeutics

Keywords

  • Choline acetyltransferase deficiency
  • Congenital myasthenic syndromes (CMSs)
  • Dok-7 myasthenia
  • Edrophonium test
  • Endplate AChE deficiency
  • Endplate AChR deficiency from receptor mutations
  • MuSK role in maturation and synapse
  • Prenatal CMS with fetal akinesia
  • Slow-channel CMSs and sodium-channel myasthenia
  • Slow-channel syndrome

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Engel, A. G. (2011). Congenital Myasthenic Syndromes. In Neuromuscular Disorders (pp. 142-149). Wiley-Blackwell. https://doi.org/10.1002/9781119973331.ch19

Congenital Myasthenic Syndromes. / Engel, Andrew G.

Neuromuscular Disorders. Wiley-Blackwell, 2011. p. 142-149.

Research output: Chapter in Book/Report/Conference proceedingChapter

Engel, AG 2011, Congenital Myasthenic Syndromes. in Neuromuscular Disorders. Wiley-Blackwell, pp. 142-149. https://doi.org/10.1002/9781119973331.ch19
Engel AG. Congenital Myasthenic Syndromes. In Neuromuscular Disorders. Wiley-Blackwell. 2011. p. 142-149 https://doi.org/10.1002/9781119973331.ch19
Engel, Andrew G. / Congenital Myasthenic Syndromes. Neuromuscular Disorders. Wiley-Blackwell, 2011. pp. 142-149
@inbook{b8f3f824932649439030292a2aec54f3,
title = "Congenital Myasthenic Syndromes",
abstract = "Congenital myasthenic syndromes (CMSs) stem from defects in endplate-associated proteins that compromise the safety margin of neuromuscular transmission by one or more distinct mechanisms. The identified syndromes stem from defects of choline acetyltransferase, acetylcholinesterase, β2-laminin, acetylcholine receptor subunits, rapsyn, MuSK, agrin, Dok-7, Nav1.4, and plectin. Distinct clinical clues can point to the disease protein but sometimes electrophysiological, structural, and genetic studies are required for diagnosis. Different types of CMSs mandate different types of therapy.",
keywords = "Choline acetyltransferase deficiency, Congenital myasthenic syndromes (CMSs), Dok-7 myasthenia, Edrophonium test, Endplate AChE deficiency, Endplate AChR deficiency from receptor mutations, MuSK role in maturation and synapse, Prenatal CMS with fetal akinesia, Slow-channel CMSs and sodium-channel myasthenia, Slow-channel syndrome",
author = "Engel, {Andrew G}",
year = "2011",
month = "9",
day = "6",
doi = "10.1002/9781119973331.ch19",
language = "English (US)",
isbn = "0470654562",
pages = "142--149",
booktitle = "Neuromuscular Disorders",
publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Congenital Myasthenic Syndromes

AU - Engel, Andrew G

PY - 2011/9/6

Y1 - 2011/9/6

N2 - Congenital myasthenic syndromes (CMSs) stem from defects in endplate-associated proteins that compromise the safety margin of neuromuscular transmission by one or more distinct mechanisms. The identified syndromes stem from defects of choline acetyltransferase, acetylcholinesterase, β2-laminin, acetylcholine receptor subunits, rapsyn, MuSK, agrin, Dok-7, Nav1.4, and plectin. Distinct clinical clues can point to the disease protein but sometimes electrophysiological, structural, and genetic studies are required for diagnosis. Different types of CMSs mandate different types of therapy.

AB - Congenital myasthenic syndromes (CMSs) stem from defects in endplate-associated proteins that compromise the safety margin of neuromuscular transmission by one or more distinct mechanisms. The identified syndromes stem from defects of choline acetyltransferase, acetylcholinesterase, β2-laminin, acetylcholine receptor subunits, rapsyn, MuSK, agrin, Dok-7, Nav1.4, and plectin. Distinct clinical clues can point to the disease protein but sometimes electrophysiological, structural, and genetic studies are required for diagnosis. Different types of CMSs mandate different types of therapy.

KW - Choline acetyltransferase deficiency

KW - Congenital myasthenic syndromes (CMSs)

KW - Dok-7 myasthenia

KW - Edrophonium test

KW - Endplate AChE deficiency

KW - Endplate AChR deficiency from receptor mutations

KW - MuSK role in maturation and synapse

KW - Prenatal CMS with fetal akinesia

KW - Slow-channel CMSs and sodium-channel myasthenia

KW - Slow-channel syndrome

UR - http://www.scopus.com/inward/record.url?scp=84885747749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885747749&partnerID=8YFLogxK

U2 - 10.1002/9781119973331.ch19

DO - 10.1002/9781119973331.ch19

M3 - Chapter

AN - SCOPUS:84885747749

SN - 0470654562

SN - 9780470654569

SP - 142

EP - 149

BT - Neuromuscular Disorders

PB - Wiley-Blackwell

ER -